Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30986316 | 1.00 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL29435144 | 0.89 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL29371790 | 0.89 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL28056 | 0.89 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL29613355 | 0.88 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5953239 | 0.88 | KIT (0.45) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL8542307 | 0.86 | KIT (0.48) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| Dimethylamine SCHEMBL8548130 | 0.84 | KIT (0.44) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| Dimethylamine SCHEMBL8546032 | 0.83 | KIT (0.44) | KITPDGFRAFGFR3KDM4EALDH1A1 | |
| SCHEMBL8546035 | 0.83 | KIT (0.43) | KITPDGFRAFGFR3SPREGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840535-B2 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11746110-B2 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-09-05 | — | — | US | disclosed |
| EP-3808746-B1 | N-[3-[2-[8-[(1H-PYRAZOL-4-YL)AMINO]IMIDAZO[1,2-A]PYRAZIN-3-YL]ETHYNYL]PHENYL]-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SHENZHEN TARGETRX INC (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-20210284646-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-09-16 | — | — | US | disclosed |
| EP-3808746-A1 | ALKYNYL (HETERO) AROMATIC RING COMPOUNDS USED FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2021-04-21 | — | — | EP | disclosed |
| EP-2755482-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Merck Sharp & Dohme Corp. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013039854-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-1945028-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | Merck & Co., Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007055942-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284646-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | ALK, BRAF, DSTYK | KIT 857/4885PDGFRA 570/4885FGFR3 202/4885 |
| US-11746110-B2 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity | ALK, WEE1, WEE2 | KIT 625/4885PDGFRA 667/4885FGFR3 259/4885 |
| US-11840535-B2 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity | ALK, BRAF, DSTYK | KIT 857/4885PDGFRA 570/4885FGFR3 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.